These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 27382574)

  • 81. The antidiabetic action of camel milk in experimental type 2 diabetes mellitus: an overview on the changes in incretin hormones, insulin resistance, and inflammatory cytokines.
    Korish AA
    Horm Metab Res; 2014 Jun; 46(6):404-11. PubMed ID: 24627103
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment.
    Lok KH; Wareham NJ; Nair RS; How CW; Chuah LH
    Pharmacol Res; 2022 Jun; 180():106237. PubMed ID: 35487405
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
    Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
    Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity.
    Marrano N; Biondi G; Borrelli A; Cignarelli A; Perrini S; Laviola L; Giorgino F; Natalicchio A
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33671882
    [TBL] [Abstract][Full Text] [Related]  

  • 85. GLP-1 - Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy.
    Holst JJ; Jepsen SL; Modvig I
    Curr Opin Pharmacol; 2022 Apr; 63():102189. PubMed ID: 35231672
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?
    Bakbak E; Terenzi DC; Trac JZ; Teoh H; Quan A; Glazer SA; Rotstein OD; Al-Omran M; Verma S; Hess DA
    Rev Endocr Metab Disord; 2021 Dec; 22(4):1171-1188. PubMed ID: 34228302
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis.
    Tang T; Abbott S; le Roux CW; Wilson V; Singhal R; Bellary S; Tahrani AA
    Diabetes Obes Metab; 2018 Mar; 20(3):745-748. PubMed ID: 29053203
    [TBL] [Abstract][Full Text] [Related]  

  • 88. GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?
    Muzurović E; Yumuk VD; Rizzo M
    J Diabetes Complications; 2023 Dec; 37(12):108647. PubMed ID: 37952274
    [No Abstract]   [Full Text] [Related]  

  • 89. Advances in the Management of Diabetes and Overweight using Incretin-based Pharmacotherapies.
    Prajapati S
    Curr Diabetes Rev; 2024; 20(7):e131123223544. PubMed ID: 37962047
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [GLP-1 and GIP receptor agonists: emerging therapies for obesity].
    Chartoumpekis D; Favre L
    Rev Med Suisse; 2023 Mar; 19(819):555-561. PubMed ID: 36950785
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Gut hormone co-agonists for the treatment of obesity: from bench to bedside.
    Nogueiras R; Nauck MA; Tschöp MH
    Nat Metab; 2023 Jun; 5(6):933-944. PubMed ID: 37308724
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Obesity and GLP-1.
    Perez-Montes DE Oca A; Pellitero S; Puig-Domingo M
    Minerva Endocrinol (Torino); 2021 Jun; 46(2):168-176. PubMed ID: 33213122
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Use of a biomimetic hydrogel depot technology for sustained delivery of GLP-1 receptor agonists reduces burden of diabetes management.
    d'Aquino AI; Maikawa CL; Nguyen LT; Lu K; Hall IA; Jons CK; Kasse CM; Yan J; Prossnitz AN; Chang E; Baker SW; Hovgaard L; Steensgaard DB; Andersen HB; Simonsen L; Appel EA
    Cell Rep Med; 2023 Nov; 4(11):101292. PubMed ID: 37992687
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    Emanuel EJ; Dellgren JL; McCoy MS; Persad G
    N Engl J Med; 2024 May; 390(20):1839-1842. PubMed ID: 38630999
    [No Abstract]   [Full Text] [Related]  

  • 95. Bariatric metabolic surgery more effective than GLP1R agonists in preventing congestive HF.
    Fernández-Ruiz I
    Nat Rev Cardiol; 2024 Jul; 21(7):438. PubMed ID: 38806634
    [No Abstract]   [Full Text] [Related]  

  • 96. Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity.
    Parums DV
    Med Sci Monit; 2024 Oct; 30():e946675. PubMed ID: 39350608
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management.
    Lian K; Zhang K; Kan C; Hou N; Han F; Sun X; Qiu H; Guo Z
    Life Sci; 2024 Aug; 351():122801. PubMed ID: 38862060
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta-analysis.
    Sarma S; Palcu P
    Obesity (Silver Spring); 2022 Nov; 30(11):2111-2121. PubMed ID: 36321278
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond.
    Tsilingiris D; Kokkinos A
    Metabolism; 2024 Feb; 151():155741. PubMed ID: 37995806
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands.
    Tanday N; Flatt PR; Irwin N
    Br J Pharmacol; 2022 Feb; 179(4):526-541. PubMed ID: 33822370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.